Stryker ($SYK) is a serial acquirer that ranks acquisitions first in its stated capital-allocation order, and its filings show about $10.0 billion of cash spent on deals from 2022 through September 30, 2026. The big ones: Vocera in 2022, Inari Medical for $4.81 billion net of cash in February 2025, and Amplitude Vascular Systems in May 2026. In October 2026 it also agreed to put about $400 million into CMR Surgical, with an option to buy the rest. The deals are paid in cash, funded by operating cash flow and bonds, with milestone payments on top. Below are the track record, the strategy, the financing, and a worked table showing what the deals actually cost and added, taken straight from the 10-K and 10-Qs.
Stryker's deal track record, by the cash-flow line
Forget press-release totals. The cleanest record of Stryker M&A is one cash-flow line: "Acquisitions, net of cash acquired," the cash that actually left Stryker minus cash in the target's bank account. Here is that line, with the main deal each filing names. Dollar figures are in millions.
| Period | Cash paid for acquisitions, net of cash acquired | Main deal named in the filing |
|---|---|---|
| 2022 | $2,563 | Vocera, $79.25 per share (February 2022) |
| 2023 | $390 | Cerus Endovascular: $289 cash plus up to $225 in milestones (May 2, 2023) |
| 2024 | $1,628 | "Various acquisitions," plus up to $400 contingent on milestones |
| 2025 | $4,960 | Inari Medical, $80 per share, $4,810 net of cash (February 2025) |
| Nine months 2026 | $481 | Amplitude Vascular Systems (AVS), $434 net cash (May 2026) |
Add it up and the line totals $10,022 million. Inari alone was about 97% of 2025's spending ($4,810 million of $4,960 million). The pattern is one large platform deal every few years, with a steady stream of tuck-ins in between.
What Stryker buys, and why
The 2025 10-K is blunt about the goal: sales growth "at the high-end" of medtech, plus a capital allocation strategy that prioritizes "(1) Acquisitions, (2) Dividends and (3) Share repurchases." The deals cluster in three places:
- Vascular is the main lane. Inari brought "minimally invasive products for the treatment of venous thromboembolism," and Stryker renamed its Neurovascular business Vascular after the deal. AVS "is developing a next-generation intravascular lithotripsy platform designed to treat complex peripheral arterial disease" and sits in the same Peripheral Vascular unit. Cerus, bought in 2023, added hemorrhagic-stroke products.
- Tuck-ins. In 2025 Stryker bought Guard Medical (negative pressure wound therapy, which fits next to Orthopaedic Instruments) and Advanced Medical Balloons (fecal management, in Medical). The 2024 deals were spread across six businesses, from Endoscopy to Joint Replacement.
- Robotics optionality. The Q3 2026 10-Q says Stryker signed an agreement in October 2026 to invest about $400 million in cash for CMR Surgical preferred equity. The agreement gives it exclusive U.S. distribution rights for the Versius robot and "an exclusive option to acquire 100%" of the remaining equity. The filing says the deal is expected to close in Q4 2026, subject to regulatory approval.
How Stryker pays for deals
Stryker pays with cash, bonds and IOUs (milestone payments). Inari and AVS were both cash deals.
- Bonds for the big one. On February 10, 2025, Stryker sold $3.0 billion of notes in four tranches, with coupons from 4.550% to 5.200%. The 8-K says proceeds from the 2030 and 2035 notes, "together with cash on hand," would fund the Inari tender offer. Those two tranches carried a 101% special mandatory redemption if the deal failed. Total debt rose from $13,597 million at the end of 2024 to $15,859 million at the end of 2025.
- Milestones. AVS came with up to $400 million in milestones, Cerus up to $225 million, and the 2024 deals up to $400 million. Stryker books each at fair value as contingent consideration, remeasures it every period and runs the changes through SG&A.
- 2026: no new bonds. In the first nine months of 2026, the $481 million of acquisitions sat alongside $1,000 million of buybacks and $1,012 million of dividends. That compares with $3,303 million of operating cash flow. No long-term debt was issued, and net short-term borrowings added $247 million. Total debt was $14,930 million on September 30, 2026, including $250 million of commercial paper. In October 2026 the board raised the buyback authorization to $3,033 million.
Stryker filed a new automatic shelf (Form S-3ASR) on November 4, 2026: capacity, not a sale.
The worked table: what M&A cost and what it added
This is the part most deal recaps skip. Every row below comes from Stryker's own filings: the FY2025 10-K and the Q3 2026 10-Q. Dollar figures are in millions.
| Line item (where it lives) | FY2025 (Inari year) | Nine months 2026 (AVS) |
|---|---|---|
| Cash paid for acquisitions, net of cash acquired (cash-flow statement) | $4,960 | $481 |
| Goodwill from the main deal (acquisitions note) | $3,191 (Inari; revised to $3,117 in the 2026 10-Qs) | $398 (AVS) |
| Intangibles from the main deal | $1,860 (developed tech, customers, other) | $402 (in-process R&D) |
| Contingent consideration booked (fair value note) | $90 assumed from Inari's own deals | $271 |
| Inventory step-up expensed (non-GAAP reconciliation) | $173 | None |
| Other acquisition and integration costs (non-GAAP reconciliation) | $335 | $61 |
| Amortization of purchased intangibles, all deals | $732 | $530 |
| Goodwill impairment, Peripheral Vascular | None (fair value 12% above carrying value) | $293 (Q3 2026) |
| Long-term debt issued (cash-flow statement) | $2,979 | $0 |
| Disclosed revenue from the deal | Inari about 2.3% of $25,116 net sales | None disclosed |
Read it top to bottom. Inari's 2025 integration bill was $508 million pre-tax: $173 million of inventory step-up plus $335 million of other costs. That came before $732 million of amortization, which covers every past deal. The other costs include $140 million of stock compensation paid on a change in control; the 10-K separately cites a $139 million charge for Inari share awards that vested on closing. Goodwill on the balance sheet rose $3,436 million in 2025, to $19,291 million.
Revenue is harder to pin down. The only Inari sales figure in the 10-K sits in the internal-control report, which excluded Inari as "approximately 2.3%" of 2025 net sales. That works out to roughly $578 million. In 2026, Inari is folded into "Vascular" ($1,579 million in the first nine months of 2026), and that line also holds neurovascular.
Then comes the impairment. At October 31, 2025, the Peripheral Vascular unit's fair value exceeded its carrying amount by only 12%, against $3,203 million of goodwill. In Q3 2026 Stryker took a $293 million charge on that unit, citing "near-term operational and supply constraints and a longer expected period to achieve anticipated growth and market recovery." The 12% cushion turned into a write-down in under a year.
The Amplitude Vascular deal: $835 million or $705 million?
The deal is real, and it has closed. The Q1 2026 10-Q says: "On May 7, 2026 we acquired Amplitude Vascular Systems, Inc. (AVS) for approximately $435 in cash and up to $400 in future milestone payments." The $835 million headline, used in places including IMA's May 2026 story on the deal, is that cash plus the maximum milestones.
The Q3 10-Q books it differently. It shows $434 million of net cash plus milestones with a fair value of $271 million, for a purchase price of $705 million net of cash acquired. Nearly all of that went to in-process R&D ($402 million) and goodwill ($398 million). That R&D covers projects "where the related product has not yet received regulatory approval," so there is no revenue to show yet. Stryker filed no 8-K for AVS. An EDGAR full-text search for the name returns only its three 2026 10-Qs.
For scale: 380.7 million shares at $310.72, the November 16, 2026 close, is about $118 billion of market value. On that basis AVS is roughly 0.6% of the company and Inari about 4%.
Where to find each number, and the mistake to avoid
Checklist for any Stryker deal:
- Cash-flow statement, investing section: "Acquisitions, net of cash acquired."
- Acquisitions note (Note 6 in the 10-K, Note 7 in the 2026 10-Qs): price, milestones and the purchase-price allocation table.
- Non-GAAP reconciliation in MD&A: the "Acquisition and integration-related costs" rows, and footnote (a), which itemizes them.
- Goodwill note and critical accounting estimates: how far fair value sits above carrying value, by reporting unit.
- Subsequent events note: deals signed after quarter-end, such as CMR Surgical.
- 8-Ks for large deals and the bonds that fund them. Our guide on how to read an 8-K covers the items.
The common mistake is reading "impact of acquisitions and divestitures" as acquisition growth. In 2025 that impact was just 0.4% company-wide. The small total hid two large moves in opposite directions: a 4.7% lift in MedSurg and Neurotechnology, Inari's segment, and a 5.7-point effect in Orthopaedics. In Orthopaedics, 3.8% constant-currency growth became 9.6% unit-volume growth once that effect was stripped out. The second mistake is adding milestones at face value. Stryker's own books carry AVS's $400 million cap at $271 million.
For more company breakdowns, see the Markets section or the I'M A STOCK TRADER homepage.
Bull/Bear Verdict
Bull Case: Stryker's M&A is unusually easy to read. One cash-flow line, a purchase-price table for each deal, itemized integration costs and disclosed goodwill headroom let a trader rebuild what Inari and AVS cost from the filings alone, without trusting a headline.
Bear Case: The same numbers hide plenty. Milestones are carried at $271 million against a $400 million cap. Acquired revenue disappears into "Vascular" after year one. Acquisitions and divestitures are netted into one percentage. And a 12% goodwill cushion became a $293 million charge within a year.
FAQ
What is Stryker's largest recent acquisition?
In the 2022–2026 filings reviewed here, it is Inari Medical: $80 per share and $4,810 million net of cash acquired. The deal closed February 19, 2025, and the closing 8-K puts total consideration at about $4.94 billion in cash.
Did Stryker buy Amplitude Vascular Systems for $835 million?
Not quite. Stryker closed the deal on May 7, 2026 for about $435 million in cash plus up to $400 million in milestones. The Q3 2026 10-Q records a $705 million purchase price, because it carries the milestones at their $271 million fair value.
Is Stryker acquiring CMR Surgical?
Not yet. The October 2026 agreement is an investment of about $400 million in preferred equity, with U.S. distribution rights and an exclusive option to buy the rest. The Q3 10-Q says it is expected to close in Q4 2026, subject to regulatory approval.
Does Stryker issue stock to pay for deals?
Not for Inari or AVS, which were paid in cash, with milestones added for AVS. In 2026 the share count fell from 382.5 million to 380.7 million by September 30 after $1,000 million of buybacks.